Detalles de la búsqueda
1.
Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial.
Future Oncol
; 17(26): 3445-3456, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34044585
2.
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
BMC Med
; 17(1): 207, 2019 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31747948
3.
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.
Breast Cancer Res Treat
; 157(2): 363-371, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27155668
4.
Underuse of anthracyclines in women with HER-2+ advanced breast cancer.
Oncologist
; 15(7): 665-72, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20576644
5.
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
Breast Cancer Res Treat
; 124(3): 607-17, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20127405
6.
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison.
BMC Cancer
; 10: 28, 2010 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20122160
7.
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies.
Breast Care (Basel)
; 15(1): 30-37, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32231495
8.
Molecular mechanisms of the D327N SHBG protective role on breast cancer development after estrogen exposure.
Breast Cancer Res Treat
; 114(3): 449-56, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18437557
9.
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
Onco Targets Ther
; 12: 2989-2997, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31114242
10.
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.
J Transl Med
; 6: 25, 2008 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-18485193
11.
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Clin Breast Cancer
; 8(5): 436-42, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18952558
12.
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study.
BMC Cancer
; 8: 209, 2008 Jul 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-18652678
13.
Volumetric modulated arc therapy (VMAT) to deliver nodal irradiation in breast cancer patients.
Med Oncol
; 35(1): 1, 2017 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29209826
14.
Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life.
Springerplus
; 5: 59, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26835238
15.
Hypofractionation with no boost after breast conservation in early-stage breast cancer patients.
Med Oncol
; 33(10): 108, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27573380
16.
Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients.
Eur J Cancer
; 41(2): 249-55, 2005 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-15661550
17.
Pituitary lesions in breast cancer patients: A report of three cases.
Oncol Lett
; 9(6): 2762-2766, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26137142
18.
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study.
Cancer Chemother Pharmacol
; 52(2): 147-52, 2003 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12764672
19.
Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
Am J Clin Oncol
; 26(1): 95-7, 2003 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-12576933
20.
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
Mol Oncol
; 8(1): 20-6, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24075779